Esteban Cesar Gabazza
6PUBLICATIONS
3CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (6)
Sort by Publication Date:
|Jan 30, 2023
Next-generation sequencing clarified why first-line treatment with osimertinib was ineffective in an autopsied case of EGFR-mutated lung squamous cell carcinoma.Tadashi Nishimura, Takumi Fujiwara, Hajime Fujimoto
|Aug 13, 2021
The role of cigarette smoking-derived pollutants in the risk of mortality in idiopathic pulmonary fibrosis.Taro Yasuma, Corina N D'Alessandro-Gabazza, Osamu Hataji
|Feb 15, 2021
Second-line therapy with first- or second-generation tyrosine kinase inhibitors in EGFR-mutated non-small cell lung cancer patients with T790M-negative or unidentified mutation.Tadashi Nishimura, Tomohito Okano, Masahiro Naito
|Mar 10, 2020
Too Premature to Deny the Potential of Thrombomodulin Alfa in Idiopathic Pulmonary Fibrosis.Tetsu Kobayashi, Osamu Hataji, Hajime Fujimoto
|Sep 14, 2018
Comparable immunoreactivity rates of PD-L1 in archival and recent specimens from non-small cell lung cancer.Yuki Nakamura, Tetsu Kobayashi, Yoichi Nishii
|Jul 07, 2018
Risks of Treating Idiopathic Pulmonary Fibrosis with a TAM Receptor Kinase Inhibitor.Corina N D'Alessandro-Gabazza, Tetsu Kobayashi, Esteban C Gabazza
Pageof 1
